Inclusion Criteria:

- Pathologically proven (either histologic or cytologic) diagnosis of Stage IIIA or
IIIB non-small cell lung cancer; excluding patients with N3 disease based on
supraclavicular or contralateral hilar adenopathy, or significant pleural /
pericardial effusion.

Exclusion Criteria:

- Patients for whom treatment is planned with a maximum dose of ≥ 66 Gy to the
ipsilateral brachial plexus

- Greater than minimal, exudative, or cytologically positive pleural effusions

- ≥ 10% weight loss within the past month

- Prior invasive malignancy (with exceptions)

- Prior radiotherapy to the region of the study cancer

- Significant co-morbidities

- Pregnancy or women of childbearing potential and men who are sexually active and not
willing/able to use medically acceptable forms of contraception

- Known allergic reactions to components of planned chemotherapy regimen